Trial Profile
A Retrospective Study Assessing Efficacy of Eculizumab Refractory Myasthenia Responsiveness in a Tertiary Care Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2020
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 21 May 2020 New trial record
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology